EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

Robert Ritzel, Sujoy Ghosh iD, Rifat Emral iD, Rachid Malek, Longyi Zeng, Maria Aileen Mabunay, Wolfgang Landgraf iD, Patricia Guyot, Paul Serafini, Divya Pushkarna iD, Rayaz A Malik iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15121 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Robert Ritzel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Angiology, München Klinik Schwabing, Munich, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the efficacy and safety of insulin glargine‐300 once daily (Gla‐300) with insulin degludec/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti‐diabetic drugs (OADs). Materials and methods A systematic literature review of randomized controlled trials was followed by an indirect treatment comparison of studies involving insulin naïve adults, inadequately controlled [glycated haemoglobin (HbA1c) ≥7.0%] on OADs, who received Gla‐300 or IDegAsp once daily. Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events.

Results

Four trials with broadly similar baseline patient characteristics were included in the meta‐analyses and indirect treatment comparison. At 24‐28 weeks, the indirect comparison of Gla‐300 to IDegAsp once daily estimated no statistically significant difference for change in HbA1c (%) from baseline [mean difference of 0.10% (95% CI: −0.20, 0.39; p = .52)]; a statistically significant mean difference of −1.31 kg (95% CI: −1.97, −0.65; p < .05) for change in body weight from baseline; statistically significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p < .05) for incidence of any hypoglycaemia; and 0.47 (95% CI: 0.25, 0.87; p < .05) for incidence of anytime confirmed hypoglycaemia (plasma glucose

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaAdultHumansInsulinInsulin AspartGlycated HemoglobinHypoglycemic AgentsInsulin GlargineBlood GlucoseInsulin, Regular, Human

Stichwörter der Autor:innen

efficacyindirect treatment comparisoninsulin degludec-insulin aspartinsulin glarginemeta-analysissafety

Substanzen

InsulinInsulin AspartGlycated HemoglobinHypoglycemic AgentsInsulin GlargineBlood GlucoseInsulin, Regular, Human

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Angiology, München Klinik Schwabing, Munich, Germany.
  • Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
  • Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara University, Ankara, Turkey.
  • Department of Internal Medicine, Setif University Hospital, Sétif, Algeria.
  • Department of Endocrinology and Metabolism, The Third Affiliated Hospital-Sun Yat-sen University, Guangzhou, China.
  • Sanofi, Global Medical, Singapore, Singapore.

ORCID-Profile: Sujoy Ghosh, Rifat Emral, Wolfgang Landgraf, Divya Pushkarna, Rayaz A Malik

Förderung

  • Sanofi

Zitieren

APA

Ritzel, R., Ghosh, S., Emral, R., Malek, R., Zeng, L., Mabunay, M. A., Landgraf, W., Guyot, P., Serafini, P., Pushkarna, D., & Malik, R. A. (2023). Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15121

Vancouver

Ritzel R, Ghosh S, Emral R, Malek R, Zeng L, Mabunay MA, et al. Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15121

BibTeX
@article{Ritzel2023,
  author = {Ritzel, Robert and Ghosh, Sujoy and Emral, Rifat and Malek, Rachid and Zeng, Longyi and Mabunay, Maria Aileen and Landgraf, Wolfgang and Guyot, Patricia and Serafini, Paul and Pushkarna, Divya and Malik, Rayaz A},
  title = {Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15121}
}
Kostenlos starten →